Bristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Zacks
Open on Zacks
Bristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

The upcoming report from Bristol Myers Squibb (BMY) is expected to reveal quarterly earnings of $1.28 per share, indicating a decline of 21.5% compared to the year-ago period. Analysts forecast revenues of $12.56 billion, representing an increase of 2.7% year over year.

The current level reflects a downward revision of 0.7% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.

Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

With that in mind, let's delve into the average projections of some Bristol Myers metrics that are commonly tracked and projected by analysts on Wall Street.

The average prediction of analysts places 'Net Sales- Zeposia' at $165.48 million. The estimate indicates a year-over-year change of +2.8%.

The consensus among analysts is that 'Net Sales- Orencia' will reach $981.41 million. The estimate indicates a change of +1.8% from the prior-year quarter.

The combined assessment of analysts suggests that 'Net Sales- Eliquis' will likely reach $4.59 billion. The estimate indicates a year-over-year change of +22.6%.

Analysts expect 'Net Sales- Yervoy' to come in at $755.79 million. The estimate suggests a change of +2.3% year over year.

Analysts forecast 'Net Sales- Abraxane- U.S.' to reach $9.24 million. The estimate indicates a year-over-year change of -61.5%.

Analysts predict that the 'Net Sales- Opdivo- U.S.' will reach $1.29 billion. The estimate indicates a year-over-year change of -11.2%.

Analysts' assessment points toward 'Net Sales- Pomalyst/Imnovid- U.S.' reaching $73.30 million. The estimate indicates a change of -87.7% from the prior-year quarter.

Based on the collective assessment of analysts, 'Net Sales- Pomalyst/Imnovid- International' should arrive at $44.90 million. The estimate indicates a year-over-year change of -43.2%.

The collective assessment of analysts points to an estimated 'Net Sales- Revlimid- U.S.' of $164.08 million. The estimate indicates a year-over-year change of -66.2%.

According to the collective judgment of analysts, 'Net Sales- Revlimid- International' should come in at $53.05 million. The estimate points to a change of -40.4% from the year-ago quarter.

The consensus estimate for 'Net Sales- Reblozyl- U.S.' stands at $592.45 million. The estimate indicates a change of +19.9% from the prior-year quarter.

It is projected by analysts that the 'Net Sales- Reblozyl- International' will reach $146.61 million. The estimate points to a change of +21.2% from the year-ago quarter.

View all Key Company Metrics for Bristol Myers here>>>

Over the past month, Bristol Myers shares have recorded returns of -2.2% versus the Zacks S&P 500 composite's -1.2% change. Based on its Zacks Rank #3 (Hold), BMY will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Bristol Myers Squibb Company (BMY): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research